Q-Line Biotech Ltd

Annual General Meeting

Q-Line Biotech Annual General Meeting

Q-Line Biotech has sent a letter to shareholders with bounced emails, providing links to the Annual Report and 16th AGM Notice, scheduled for September 30, 2026.

Annual Report

Q-Line Biotech Annual Report

Q-Line Biotech Limited has submitted its Annual Report for the financial year 2025-26. The full document is accessible via the provided company website link.

Board Meeting Outcome

Q-Line Biotech Board Meeting Outcome

Q-Line Biotech approved the Board's Report, notice for the 16th AGM, and re-appointment of two Whole Time Directors and the Cost Auditor.

Other Announcement

Q-Line Biotech Other Announcement

Q-Line Biotech Limited has re-appointed M/s. P S P & Associates as Cost Auditors for a 12-month term.

Execution

12 months

PartnershipAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Q-Line Biotech Partnership

Q-Line Biotech amended its license agreement with Boule Medical AB, Sweden. The revision includes a 25% reduction in license/royalty costs effective from July 2026.

From

Boule Medical AB

Execution

5 years

Financial ResultsAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Q-Line Biotech H2 FY26 Results: Net Profit ₹34.4 Cr, Up 290.9% YoY

Q-Line Biotech Ltd reported revenue from operations of ₹197.9 Cr (-8.6% YoY) and net profit of ₹34.4 Cr (+290.9% YoY) for H2 FY26.

Key figure

Net profit ₹34.4 Cr · +290.9% YoY